A Study of Eloralintide (LY3841136) in Participants With Persistent Obesity Who Are Treated With a Weekly Incretin

Prior treatment

• Have a prior or planned surgical treatment for obesity (liposuction, cryolipolysis, or abdominoplasty allowed if performed \>1 year before screening)
• Have a prior or planned endoscopic procedure and/or device-based therapy for obesity (prior device-based therapy acceptable if device removal was more than 6 months prior to screening)
• Have taken any of the following antihyperglycemic medications within 90 days before screening:
  • dipeptidyl peptidase-4 (DPP-4) inhibitors
  • amylin analogs
  • insulin
• Have had within 90 days prior to screening:
  • heart attack
  • stroke
  • coronary artery revascularization
  • unstable angina, or
  • hospitalization due to congestive heart failure

Other illness

• Have type 1 diabetes
• Have a history or diagnosis of New York Heart Association Functional Classification Class IV congestive heart failure

• Are on stable incretin therapy at screening
• With persistent obesity or overweight defined as:
  • ≥30 kg/m2 OR
  • ≥27 kg/m2 with at least one existing obesity related complication at screening:
  • hypertension
  • dyslipidemia
  • obstructive sleep apnea
  • cardiovascular disease (for example, ischemic cardiovascular disease, New York Heart Association Functional Class I-III heart failure), or
  • type 2 diabetes
• Have a stable body weight (\<5% body weight change) at screening